McMichael Bryan J 4

What Happened

• Bryan J. McMichael, Chief Financial Officer of Coherus Oncology (CHRS), received equity awards on January 22, 2026: 112,500 restricted stock units (RSUs) and 225,000 derivative awards/options. Both grants were recorded at $0.00 purchase price (awards, not open-market purchases), so no cash changed hands at grant.

Key Details

• Transaction date: January 22, 2026; Form 4 filed January 26, 2026 reporting these grants.
• Award amounts and reported values:
  • 112,500 RSUs @ $0.00 (Footnote F1)
  • 225,000 derivative award/option-related shares @ $0.00 (Footnote F2)
• Vesting/terms (footnotes):
  • F1 (RSUs): 50% vest May 20, 2027; remaining 50% vest March 20, 2029, subject to continued service.
  • F2 (options/derivative): 1/4 of the total vests on the one-year anniversary of Jan 22, 2026, then 1/48th of the total vests each subsequent month (standard multi-year monthly vesting), subject to continued service.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No sale or immediate disposition reported; these are time-based compensation awards.

Context

• These are compensation grants (awards), not purchases or sales. Because they vest over time, they are typical retention/incentive awards and do not represent an immediate market buy or sell by the insider.
• For retail investors, awarded RSUs/options signal management compensation alignment with shareholder value over future vesting periods but do not necessarily indicate near-term insider buying or selling.